References for Cytochrome P450 Drug Interaction Table: 2C9
These pages contain all the literature citations referenced in the Cytochrome P450 Drug Interaction Tables (both the extensive research-oriented table and the concise clinical table). Most of these citations are hyperlinks, which bring up the abstract in the NLM's PubMed database.
Click on the [ PubMed ] link after the drug name to perform a live MedLINE search of articles possibly related to that drug and Cytochrome P450.
Entries are organized by mode of activity (substrate, inhibitor, inducer) within specific isoform. You can quickly branch to a section by clicking on the appropriate link here:
1A2 | 2B6 | 2C8 | 2C19 | 2C9 | 2D6 | 2E1 | 3A457
Use Ctrl-F to find all or part of the name or word for which you are searching.
amitriptyline:
PubMed
Cytochrome P4502C9: an enzyme of major importance in human drug
metabolism.
Miners JO, Birkett DJ
Br
J Clin Pharmacol 1998 Jun;45(6):525-38
celecoxib:
PubMed
NOT candesartan :
PubMed
Candesartan cilexetil: a review of its preclinical pharmacology.
Nishikawa K, Naka T, Chatani F, Yoshimura Y
J
Hum Hypertens 1997 Sep;11 Suppl 2:S9-S17
Pharmacokinetic drug interaction studies with candesartan
cilexetil.
Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Hogemann
A
J
Hum Hypertens 1997 Sep;11 Suppl 2:S31-S35
Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan
cilexetil in healthy volunteers.
van Lier JJ, van Heiningen PN, Sunzel M
J
Hum Hypertens 1997 Sep;11 Suppl 2:S27-S28
diclofenac:
PubMed
In vivo inhibition profile of cytochrome
P450tb (CYP2C9) by (±)-fluvastatin.
Transon C, Leemann T, Vogt N, Dayer P
Clin
Pharmacol Ther 1995;58(4):412-417
fenofibrate: PubMed
Fenofibrate potentiates warfarin effects.
Kim KY, Mancano MA.
Ann Pharmacother. 2003 Feb;37(2):212-5.
fluoxetine:
PubMed
Cytochrome P4502C9: an enzyme of major importance in human drug
metabolism.
Miners JO, Birkett DJ
BrJ Clin Pharmacol 1998 Jun;45(6):525-38
fluvastatin:
PubMed
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin:
effect on human cytochrome P-450 and implications for metabolic drug
interactions.
Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson
WT
Drug
Metab Dispos 1999 Mar;27(3):410-6
glimepiride
Pubmed
glipizide:
PubMed
glyburide:
PubMed
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers..
Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I.
Clin Pharmacol Ther 2002 Apr;71(4):286-96
ibuprofen:
PubMed
Stereo- and nonstereospecific oxidation by
P450tb (CYP2C): The major elimination pathway of (+/-)
-ibuprofen.
Leeman, T., Bonnabry, P., and Dayer, P
Clin Pharmacol Ther 55:208, 1994
irbesartan:
PubMed
lornoxicam:
PubMed
Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human.
Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H.
Drug Metab Dispos. 2005 Jun;33(6):749-53.
Eur J Clin Pharmacol. 1996; 49:305-308.
Drug Metab Dispos. 2000; 28:161-168.
Drug Metab Dispos. 2004; 32:7-9.
Br J Clin Pharmacol. 2005; Jan;59(1):14-7.
losartan:
PubMed
A mutation in CYP2C9 is responsible for decreased metabolism of losartan.
Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman SA. Bjornnson T, Lo M-W, Goldberg M
Clin Pharmacol Ther 1996;59(2): 215 Abst.
naproxen:
PubMed
Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic
O-demethylation of R- and S-naproxen.
Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ
Biochem
Pharmacol 1996 Apr 26;51(8):1003-1008
nateglinide
Pubmed
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ.
Clin Pharmacol Ther. 2003 Oct;74(4):380-7
phenytoin:
PubMed
Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver
cytochrome P4502C9.
Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ
Biochem
Biophys Res Commun. 1991;175(3):1112-1118
Fluconazole-induced symptomatic phenytoin toxicity.
Cadle RM, Zenon GJ III, Rodriguez-Barradas MC, Hamill RJ
Ann
Pharmacother 1994;28(2) 191-194
piroxicam:
PubMed
Involvement of multiple cytochrome P450 isoforms in naproxen
O-demethylation.
Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR
Eur
J Clin Pharmacol. 1997; 52(4): 293-298
Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting
the sole involvement of cytochrome P450 2C9.
Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR
Biochem
Pharmacol. 1996 Oct 25; 52(8): 1305-1309
rosiglitazone:
PubMed
suprofen:
PubMed
The substrate binding site of human liver cytochrome P450 2C9: an approach
using designed tienilic acid derivatives and molecular modeling.
Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D
Biochemistry
1995 Aug 22;34(33):10365-10375
tamoxifen:
PubMed
Delineation of human cytochromes P450 involved in the metabolism of
tamoxifen.
Daniels, L., Blankson, E.A., Henderson, C.J., Harris, A.H., Wolf, C.R., Lennard,
M.S., and Tucker, G.T
Br J Clin Pharmacol 33:153P, 1992
torsemide:
PubMed
Human hepatic Cytochrome P450 catalyses the
rate-limiting pathway of torsemide metabolism.
Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ
J
Pharmacol Exp Ther 1995;272(3):1076-1081
tolbutamide:
PubMed
Putative active site template model for cytochrome
P4502C9 (Tolbutamide hudroxylase).
Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS, Smith DA
Drug
Metabolism and Disposition 1996;24(2):260-266
NOT valsartan:
PubMed
Pharmacokinetics of valsartan in patients with liver disease.
Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G,
Waldmeier F, Sioufi A, Mullins F
Clinical
Pharmacology and Therapeutics, 62 (3) 272-278 1997
S-warfarin:
PubMed
Possible interaction between warfarin and fluconazole.
Gericke KR
Pharmacotherapy
1993;13(5):508-509
Possible potentiation of warfarin by fluconazole.
Seaton TL, Celum C.L., Black DJ
Drug
Intelligence Clin Pharmacol 1990;24:1177-1178
Interactions of warfarin with drugs and food.
Wells PS, Holbrook AM, Crowther NR, Hirsh J
Ann
Intern Med 1994;121:676-683
Inhibition of the human cytochrome P450- dependent metabolism of warfarin
by fluconazole: in vitro studies.
Kunze KL, Wienkers LC, Thummel KE, Trager WF
Drug
Metab Dispos 1996;24(4):414-421
A metabolically based drug interaction between fluconazole and warfarin:
in vivo studies.
Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans
JS, Bauwens JE, Trager WF
Drug
Metab Dispos 1996;24(4):422-428
2C9 INHIBITORS
| » AMIODARONE |
[ PubMed ] |
| Article | Mechanism of warfarin potentiation by amiodarone: dose--and concentration-dependent inhibition of warfarin elimination. |
| Authors | Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U, Bank H. |
| Link to Abstract | Eur J Clin Pharmacol 1985;28:257-261.
|
| Article | Steady-state interaction between amiodarone and phenytoin in normal subjects. |
| Authors | Nolan PE, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. |
| Link to Abstract | Am J Cardiol 1990;65:1252-1257. |
| Info | www.rxlist.com |
| » FLUCONAZOLE |
[ PubMed ] |
| Article | Effect of fluconazole on the disposition of phenytoin. |
| Authors | Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EU, Harrison NJ, Schentag JJ. |
| Link to Abstract | Clin Pharmacol Ther 1991;49:420-425.
|
| Article | Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. |
| Authors | Kunze KL, Wienkers LC, Thummel KE, Trager WF. |
| Link to Abstract | Drug Metab Dispos. 1996 Apr;24(4):414-21.
|
| Article | Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. |
| Authors | Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. |
| Link to Abstract | Clin Pharmacol Ther. 2006 Jan;79(1):125-33.
|
| Article | Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. |
| Authors | Kaukonen KM, Olkkola KT, Neuvonen PJ. |
| Link to Abstract | Eur J Clin Pharmacol. 1998 Feb;53(6):445-9.
|
| Info | www.rxlist.com |
fluvastatin:
PubMed
In vivo inhibition profile of cytochrome
P450tb (CYP2C9) by (±)-fluvastatin.
Transon C, Leemann T, Vogt N, Dayer P
Clin
Pharmacol Ther 1995;58(4):412-417
fluvoxamine:
PubMed
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro
studies with tolbutamide and (S)-warfarin using human liver
microsomes.
Hemeryck A, De Vriendt C, Belpaire FM
Eur
J Clin Pharmacol 1999 Feb;54(12):947-51
isoniazid:
PubMed
Clinical importance of the interaction of phenytoin
and isoniazid: a report of the Boston Collaborative Drug Surveillance
Program.
Miller RR, Porter J, Greenblatt DJ
Chest
1979;75(3):356-358
lovastatin:
PubMed
Warfarin Interaction.
Ahmad S
Arch
Int Med 1990;150:2407-2408
phenylbutazone:
PubMed
Stereochemical aspects of warfarin drug interactions:
Use of a combinned pharmacokinetic- pharmacodynamic model.
Chan E, McLachlan A, O'Reilly, Rowland M
Clin
Pharmacol Ther 1994;56(3):286-294
probenicid:
PubMed
Naproxen-probenecid interaction.
Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E
Clin
Pharmacol Ther 1978 Dec;24(6):706-713
sertraline:
PubMed
sulfamethoxazole:
PubMed
Formation and disposition of sulfamethoxazole
hydroxylamine (SMX-MA).
Spielberg SP, Nuss CE, Cribb AE
Clin Pharmacol Ther 1995;57(2):221 Abst.
sulfaphenazole:
PubMed
In vitro inhibition studies of tolbutamide hydroxylase
activity of human liver microsomes by azoles, sulphonamides, and
quinolines.
Back DJ, Tjia JF, Karbwang J, Colbert J
Br
J Clin Pharmacol 1988;26:23-29
teniposide:
PubMed
Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in
the CYP2C subfamily.
Relling MV, Aoyama T, Gonzalez FJ, Meyer UA
J
Pharmacol Exp Ther 1990 Jan;252(1):442-7
ticlopidine:
PubMed
Ticlopdine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19.
Donahue SR, Flockhart DA, Abernethy DR, Ko JW
Br
Clin Pharmacol Ther 1997 Nov;62(5):572-7
trimethoprim:
PubMed
voriconazole :
PubMed
Effect of voriconazole on the pharmacokinetics of diclofenac.
Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, Valtonen M, Laine K.
Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
Drug-drug interaction of antifungal drugs
Niwa T, Shiraga T, Takagi A
Yakugaku Zasshi. 2005 Oct;125(10):795-805.
zafirlukast:
PubMed
(Accolate®) Prescriber's Letter 1996;3(10) 55. (October)
2C9 INDUCERS
rifampin:
PubMed
secobarbital:
PubMed
Stereochemical aspects of warfarin drug interactions: use of a combined
pharmacokinetic-pharmacodynamic model.
Chan E, McLachlan A, O'Reilly R, Rowland M
Clin
Pharmacol Ther 1994 Sep;56(3):286-294
|